STAT News

MARCH 10, 2023

By law, Medicare will have to take a medication’s efficacy and its research and development costs into account when it starts to negotiate drug prices — but recent research shows pharma companies ignore those factors when they pick prices for their products. Continue to STAT+ to read the full story…

Drugs 98

Drugs Pharma Companies Research Production 98

Pharmaceutical Technology

FEBRUARY 10, 2023

On November 22, 2022, the FDA approved CSL Behring’s Hemgenix (etranacogene dezaparvovec), the first gene therapy treatment for hemophilia B, with a staggering manufacturer price of $3.5 million, according to GlobalData’s Price Intelligence (POLI), making it the most expensive drug in the world.

Gene Therapy 263

Gene Therapy Marketing Gene Drugs 263

World of DTC Marketing

JULY 20, 2022

A new analysis released Wednesday by Patients for Affordable Drugs estimates that pharmaceutical companies in the U.S. have raised drug prices 1,186 times so far this year. Patients for Affordable Drugs found that between June 24 and July 5, pharmaceutical companies increased prices for 133 products.

Packaging 183

Packaging Packaging Drugs Vaccination 183

STAT News

OCTOBER 27, 2022

Amid sporadic shortages of a drug that is essential in preparing patients for lifesaving, cancer-fighting treatments, one manufacturer has returned to the market — but is selling its medicine for 10 to 20 times the prices offered by the only other companies with available supplies.

Medicine 111

Medicine Manufacturing Marketing Drugs 111

STAT News

JANUARY 6, 2023

Food and Drug Administration has granted accelerated approval to the widely anticipated Alzheimer’s drug from Eisai and Biogen, a key question is the extent to which payers — private and public — will cover the treatment. Such decisions are based on myriad factors, starting with the average $26,500 price tag.

Drugs 119

Drugs Clinical Trials Clinical Trials Medicine 119

Medical Xpress

MARCH 8, 2023

Failure to enroll enough participants in trials can delay the arrival of new therapies in the clinic and inflate their eventual price tags. For example, a drug that proves effective for White patients might not work as well in people of other races or ethnicities.

Clinical Trials 105

Clinical Trials Clinical Trials Trials Drugs 105

Pharmaceutical Technology

MAY 19, 2023

DMTs for MS have a high price tag, particularly in the US. According to GlobalData’s recent Multiple Sclerosis: Seven-Market Drug Forecast and Market Analysis to 2030 – Update report, which identified 19 DMTs marketed for MS in the US, the average annual cost of therapy increased by 9% between 2020 and 2022.

Marketing 246

Marketing Development Drugs 246

BioSpace

JULY 11, 2021

Adulhelm's proposed price tag of $56,000 per patient per year is hardly the most expensive drug on the market, but controversy regarding packaging and pricing continues.

Packaging 78

Packaging Packaging Marketing Drugs 78

STAT News

MARCH 10, 2023

Enjoy, and see you soon … By law, Medicare will have to take a medication’s efficacy and its research and development costs into account when it starts to negotiate drug prices — but recent research shows pharma companies ignore those factors when they pick prices for their products , STAT explains. Two

Insulin 96

Insulin Pharmacy Pharma Companies Drugs 96

World of DTC Marketing

SEPTEMBER 9, 2021

SUMMARY: Allowing Medicare to negotiate drug prices is popular with voters because the media has been focused on the high price of some drugs, but this measure won’t lead to lower healthcare costs. If pharma is a business, they will find a way to develop, buy, or acquire new drugs. healthcare.

Drugs 222

Drugs Pharmacy Clinical Trials Clinical Trials 222

STAT News

JULY 14, 2022

At issue is the extent to which a drug company must describe how to replicate its newly invented medicines when applying for patents, notably biologics. Continue to STAT+ to read the full story…

Medicine 98

Medicine Marketing Drugs 98

World of DTC Marketing

SEPTEMBER 7, 2022

In pharma, growth depends on new products with hefty price tags when over 80% of voters want lower costs for their prescription drugs. They relied so much on a new drug that they tried to market a product with bad science behind it. The pharma industry is a giant behemoth that needs new drugs to survive and grow.

Pharma Companies 210

Pharma Companies Marketing Drugs Production 210

World of DTC Marketing

SEPTEMBER 24, 2021

This drug was never about patients; it was about a company whose ego got too big and needed a savior in the form of a medicine that could bring in hundreds of millions of dollars. They had a new MS drug that was the talk of the industry and an exciting pipeline. I remember when Biogen was an exciting new biotech based in Westin.

Drugs 222

Drugs Pharma Companies Doctors Doctor 222

Pharmaceutical Technology

DECEMBER 15, 2022

In an expanded version of the sales forecast from GlobalData’s June 2022 publication, Cardiomyopathies: Global Drug Forecast and Market Analysis , the global cardiomyopathies market is expected to grow from $3.07bn last year to $9.63bn in 2031. The second highest contributing market is APAC, generating 33.2%

Marketing 130

Marketing Sales Clinical Trials Clinical Trials 130

STAT News

OCTOBER 6, 2022

… Multimillion-dollar prices for a rival’s treatments with the potential to cure rare diseases are “in the right ballpark,” according to Stuart Arbuckle, chief operating officer at Vertex Pharmaceuticals, which is preparing to market its own treatment for sickle-cell disease , Bloomberg News tells us. Even

Gene Therapy 98

Gene Therapy Gene Insulin Drugs 98

Pharmaceutical Technology

JUNE 29, 2022

The US Food and Drug Administration (FDA) put a high-profile bluebird bio trial for sickle cell disease on partial clinical hold, and advisory panels deliberated over decisions involving gene therapies for amyotrophic lateral sclerosis (ALS), cerebral adrenoleukodystrophy (CALD), and beta-thalassemia.

Drugs 246

Drugs FDA Approval Marketing Development 246

pharmaphorum

DECEMBER 24, 2021

The anti-amyloid drug, which also claimed a breakthrough tag from the FDA in July, is being developed for the treatment of early-stage Alzheimer’s disease. The $56,000-a-year price tag for the drug, which has now been cut in half in the US, also hasn’t helped the drugmakers make a case for Aduhelm with US payers.

Drugs 110

Drugs FDA Approval Trials Marketing 110

Pharmaceutical Technology

JULY 14, 2022

The commercial investment required to research and develop an innovative drug, prove its safety and efficacy, and bring it to market is staggering. Most famously, the US passed its Orphan Drug Act in 1983, providing innovators with financial motivation to develop orphan drugs and meet the needs of these forgotten patients.

Drugs 147

Drugs Medicine Marketing Development 147

XTalks

DECEMBER 13, 2023

The US Food and Drug Administration (FDA) has approved the first gene therapies for the treatment of sickle cell disease, approving two on the same day. Vertex-CRISPR’s Casgevy has a US list price of $2.2 Vertex-CRISPR’s Casgevy has a US list price of $2.2 million and bluebird’s Lyfgenia is 40 percent higher at $3.1

Gene Therapy 98

Gene Therapy FDA Approval Gene In-Vivo 98

Rethinking Clinical Trials

JUNE 7, 2023

The drugs were administered open label and all patients were given a low dose of aspirin. The study drug was mailed directly to participants, and at the end of the trial participants were instructed to destroy the drug. The price for Apixaban was $600 per bottle/$6M, and the price for warfarin was $50K.

Clinical Trials 130

Clinical Trials Clinical Trials Trials Cardiology 130

XTalks

JULY 12, 2021

The US Food and Drug Administration’s (FDA) recent approval of Biogen’s Alzheimer’s drug Aduhelm (aducanumab) was met with a lot of backlash, prompting the health agency to narrow its recommendation of the drug for mild forms of the disease. All of this for a drug that has shown questionable clinical benefits, critics say.

Drugs 98

Drugs Clinical Trials Clinical Trials Trials 98

World of DTC Marketing

JUNE 23, 2021

Source: Fierce Pharma If that enthusiasm pans out in the long run, it could mean at least 300,000 patients taking the drug, or $10 billion to $15 billion in peak Aduhelm from U.S. One agency FDA adviser, resigning from his committee post in protest, called it “probably the worst drug approval decision in recent U.S. government.

Drugs 218

Drugs FDA Approval Doctors Doctor 218

pharmaphorum

NOVEMBER 19, 2020

Novartis/Genentech’s eye drug Lucentis could be the next big blockbuster to face competition from cheaper biosimilars after its US patent expired this year – and Samsung Bioepis and Biogen are closing in after the FDA accepted a filing for their cut-price rival.

FDA Approval 63

FDA Approval Marketing Drugs Clinical Development 63

pharmaphorum

JUNE 8, 2021

The FDA “has failed in its responsibility to protect patients and families from unproven treatments with known harms” in approving Biogen’s Alzheimer’s disease drug Aduhelm. It said the drug was the first to treat the underlying mechanism in Alzheimer’s rather than addressing symptoms.

Drugs 98

Drugs Marketing FDA Approval Trials 98

XTalks

NOVEMBER 30, 2022

The therapy is now officially the world’s most expensive drug at $3.5 Hear more about the therapy and how the high price tag of the new drug is actually lower than the cost of treating Hemophilia B patients over their lifetimes with current conventional treatments. million per dose.

Gene Therapy 52

Gene Therapy Life Science Gene FDA Approval 52

pharmaphorum

AUGUST 21, 2022

There is still a pressing need for antidepressant therapies that can start to work more quickly than current tricyclic or selective serotonin reuptake inhibitor drugs can take weeks to elevate mood, placing severely affected patients at risk of self harm before they kick in. Photo by Sydney Sims on Unsplash.

Drugs 98

Drugs FDA Approval Production Marketing 98

Intouch Solutions

JULY 27, 2021

American politicians have been aware of, and looking for solutions to, drug pricing and affordability issues for literally decades. In their letter, “ Drug Pricing Reform in 2021 – Going Big or Going Bipartisan? government lowered risk by supporting trials, guaranteeing contracts, and negotiating a lower price.

Drugs 52

Drugs Marketing Vaccination Vaccine 52

Drug Discovery World

MAY 22, 2023

While the global economic landscape faces a major crisis and biotech is not recession-proof, cell and gene therapy (CGT) has continued to progress with acquisitions, breaking ground on new facilities and approvals across the year – not limited to the breakout of the world’s most expensive drug. But are these price tags a barrier to access?

Gene Therapy 52

Gene Therapy Gene Drugs Contamination 52

Drug Discovery World

JANUARY 30, 2024

Joel Eichmann, Co-Founder and Managing Director, Green Elephant Biotech, agrees that prices need to come down significantly for CGT to be widely available. Pricing and reimbursement continues to be a challenge we address as a field. Increased clinical data and evidence of cost-effectiveness can improve coverage.

Gene Therapy 71

Gene Therapy Manufacturing Gene Clinical Trials 71

Pharmaceutical Technology

FEBRUARY 22, 2023

The legal dispute is centered around rival cholesterol-lowering drugs produced by the two companies, which were approved in the summer of 2015. Both drugs are monoclonal antibodies that inhibit the protein PCSK9. Both drugs come with a high price tag. Amgen’s Repatha was greenlit a month later.

Antibody 262

Antibody Drugs Sales Protein 262

pharmaphorum

APRIL 26, 2021

The initiative was supported by grants from UCB and Pfizer and provided health information in the form of immersive experiences aimed at patients prescribed biologic drugs to treat the disease. The company halted development before it eventually sold its digital health unit back to Eric Careel, co-founder of Withings, the following year.

Development 121

Development Medicine Production Marketing 121

XTalks

NOVEMBER 24, 2022

In a pivotal approval, the US Food and Drug Administration (FDA) has given the nod to a new gene therapy called Hemgenix (etranacogene dezaparvovecfor) for the treatment of adults with the genetic blood disorder hemophilia B (congenital Factor IX deficiency). With a list price of $3.5

Gene Therapy 52

Gene Therapy Gene FDA Approval Genetics 52

pharmaphorum

OCTOBER 21, 2021

Analysts were predicting sales of Biogen’s recently approved Alzheimer’s therapy Aduhelm may start to gather a little momentum in the third quarter, but the drug seems to be going into reverse. million in sales for the drug in the second quarter. Biogen reported $1.6

Sales 121

Sales Doctors Doctor Gene Therapy 121

XTalks

JUNE 9, 2021

Biogen has been working vigorously over the past couple of years to get its potentially disease-modifying drug Aduhelm (aducanumab) approved for Alzheimer’s disease, and it has finally happened. This Monday, the US Food and Drug Administration (FDA) granted accelerated approval to the drug for the treatment of the disease.

Drugs 98

Drugs Clinical Trials Clinical Trials Trials 98

Drug Discovery World

DECEMBER 20, 2022

World’s most expensive drug. million, making it the world’s most expensive drug. . Concerns about the high price tag have been raised in an article in Nature, particularly whether it will be affordable for low to middle-income countries. . A one-time treatment with etranacogene dezaparvovec costs US$3.5

Gene Therapy 52

Gene Therapy Gene Clinical Trials Clinical Trials 52

pharmaphorum

NOVEMBER 19, 2021

The cost-effectiveness agency had turned down Evrysdi (risdiplam) in draft guidance published in June, saying it was too expensive, but after negotiations with Roche has reached a deal that will make the drug available to around 1,500 people in England. million price tag make it is the most expensive treatment ever approved for NHS funding.

Drugs 98

Drugs Gene Therapy Genetic Disease Gene 98

pharmaphorum

JANUARY 21, 2022

“It has become clear that the medicines of the 20 th century, the so-called blockbuster era, are gradually being replaced by drugs designed for smaller groups, specific indication, and even for individual patients,” said Jo De C**k, CEO of Belgium’s National Institute for Health and Disability Insurance. WHO is OMI?

Medicine 52

Medicine Marketing Manufacturing Production 52